Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 19/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.58 |
| ▸ | HTR1A | P08908 | 1/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.58 |
| ▸ | HRH2 | P25021 | 1/20 | 0.58 |
| ▸ | HTR1D | P28221 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 1/20 | 0.58 |
| ▸ | HTR2B | P41595 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2785375 | 1.00 | HRH3 (0.65) | HRH3KCNH2CHRM2CHRM4HTR1A | |
| SCHEMBL2785748 | 0.88 | HRH3 (0.62) | HRH3KCNH2CHRM2CHRM4HTR1A | |
| SCHEMBL2785743 | 0.88 | HRH3 (0.62) | HRH3KCNH2CHRM2CHRM4HTR1A | |
| SCHEMBL2785537 | 0.86 | HRH3 (0.61) | HRH3KCNH2CHRM2CHRM4HTR1A | |
| SCHEMBL2786126 | 0.84 | HRH3 (0.59) | HRH3KCNH2CHRM2CHRM4HTR1A | |
| SCHEMBL2785141 | 0.84 | HRH3 (0.61) | HRH3KCNH2CHRM2CHRM4HTR1A | |
| SCHEMBL2785138 | 0.84 | HRH3 (0.61) | HRH3KCNH2CHRM2CHRM4HTR1A | |
| SCHEMBL2785494 | 0.83 | HRH3 (0.67) | HRH3CHRM2CHRM4HTR1ACHRM5 | |
| SCHEMBL2785496 | 0.83 | HRH3 (0.67) | HRH3CHRM2CHRM4HTR1ACHRM5 | |
| SCHEMBL13863629 | 0.82 | HRH3 (0.74) | HRH3KCNH2CHRM2CHRM4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538138-B2 | Amines as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES (US) | 2009-05-26 | — | — | US | claimed |
| US-20050192277-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2005-09-01 | — | — | US | claimed |
| US-20020169188-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-11-14 | — | — | US | claimed |
| EP-2258694-A1 | Amines as histamine-3 receptor ligands and their therapeutic applications | Abbott Laboratories (US) | 2010-12-08 | — | — | EP | disclosed |
| US-7538138-B2 | Amines as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES (US) | 2009-05-26 | — | — | US | disclosed |
| US-6969730-B2 | Amines as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES (US) | 2005-11-29 | — | — | US | disclosed |
| US-20050192277-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2005-09-01 | — | — | US | disclosed |
| EP-1370546-A2 | NOVEL AMINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | Abbott Laboratories (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20020169188-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002074758-A2 | NOVEL AMINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192277-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH2 | HRH3 1/4885KCNH2 1106/4885CHRM2 83/4885 |
| US-20020169188-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | HRH3 1/4885KCNH2 948/4885CHRM2 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.